Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

June 15, 2018: By Joan McKenna

Avedro’s Photrexa formulations for corneal cross-linking will get a specific J code for billing under a preliminary decision from the Centers for Medicare and Medicaid Services, Avedro announced June 12.

The decision is expected to be finalized in November 2018 and to become effective Jan. 1, 2019, Avedro said.

Claims submitted with a product specific J codes under the Healthcare Common Procedure Coding System tend to be processed faster than those with a miscellaneous code, which requires manual review.

Photrexa formulations are indicated for use with the KXL System for cross-linking to treat progressive keratoconus and corneal ectasia following refractive surgery.

Avedro, founded in 2008, gained US approval for its crosslinking system in 2016. The company said in November 2017 that 10 thousand procedures had been performed in the US at 250 sites.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility